| B-03 Praveen Thokala Overview and implementation of multi criteria decision analysis (MCDA) for benefit-risk assessment Wednesday 09:00-09:30 |
| B-04 Andreas Kouroumalis European regulatory views on benefit-risk assessment methodologies - role of MCDA and other model-based approaches Wednesday 09:30-10:00 |
| B-05 Kevin Marsh Current practices and gaps in benefit-risk assessment: opportunities for combining MCDA with model-based approaches Wednesday 10:00-10:30 |
| B-07 Neeraj Gupta Model-Informed Drug Development (MIDD) for ixazomib, an oral proteasome inhibitor Wednesday 12:00-12:20 |
| B-08 Nadia Terranova Simulation analysis of absolute lymphocytes counts (ALC) and relapse rate (RR) following cladribine (re-)treatment rules in subjects with relapsing-remitting multiple sclerosis (RRMS) Wednesday 12:20-12:40 |
